Equine Cord Blood Mesenchymal Stromal Cells Have Greater Differentiation and Similar Immunosuppressive Potential to Cord Tissue Mesenchymal Stromal Cells.

The research article explores the therapeutic potentials of equine (horse) Mesenchymal stromal cells (MSCs) derived from umbilical cord tissue and cord blood, with findings suggesting cord blood MSCs have greater differentiation capacity while both types have similar immunosuppressive potentials.

Study Overview

• The study hinges on the clinical potential of stem cells, specifically MSCs, in veterinary medicine. It discusses the benefits of MSCs derived from neonatal sources like umbilical cord tissue (CT-MSCs) and cord blood (CB-MSCs). These sources are non-invasive and provide an opportunity to study the cells before application.
• The purpose of the study is to compare the progenitor and non-progenitor functions of CB-MSCs and CT-MSCs, focusing on differentiation potential and immunomodulatory capacity specifically.
• Based on previous observations, the researchers hypothesized that though both MSC types would have similar immune-related properties, CB-MSCs would be better suited to differentiation, a key factor in targeted cell therapy.

Analysis and Findings

• The study examined equine CB-MSCs and CT-MSCs using various cell markers (CD90, CD105, CD29, CD44, CD146, NG2, and α-SMA). They found that CB-MSCs had medium to high levels of expression of pericyte surface markers CD146 and NG2, unlike CT-MSCs where these markers were absent.
• In terms of differentiation potential, the researchers found that CB-MSCs were more osteogenic (develop bone) and chondrogenic (develop cartilage), based on the increased levels of alkaline phosphatase activity and glycosaminoglycan content respectively.
• On an immunosuppressive front, both CB-MSCs and CT-MSCs were found to suppress stimulated lymphocyte proliferation to the same degree, confirming their shared immunomodulatory potential.

Conclusions

• The research concludes that the tissue source for MSCs should be chosen carefully, considering the intended application. If a treatment plan is reliant on a progenitor-based strategy, CB-MSCs could be a more effective choice due to their superior differentiation potential.
• However, if the treatment approach requires immunomodulatory properties, both CB-MSCs and CT-MSCs would be similarly suitable. This comparability between the two MSC types underscores the importance of selecting the correct tissue source based on the therapeutic goals.